The incidence of leptomeningeal carcinomatosis (LC) has increased in patients with metastatic non-small-cell lung cancer (NSCLC) because of recent improvements in survival. The clinical features and prognostic factors of LC in NSCLC patients, however, have not been well identified. The aim of this study was to identify the clinical features and prognostic factors of NSCLC patients with LC. Methods: One hundred and forty-nine consecutive NSCLC patients with cytologically proven LC diagnoses between 2001 and 2009 at Samsung Medical Center were retrospectively reviewed. Results: The median age was 58 years (range, 34-80) with most patients (135, 95%) having histology indicating adenocarcinoma. Twenty-six patients (17.4%) had LC at the initial presentation of lung cancer. Treatment for LC consisted of intrathecal chemotherapy (ITC) alone in 44 patients, ITC plus systemic therapy in 18 patients, ITC plus radiotherapy in 29 patients, all three treatments in 18 patients, and other treatments without ITC in 20 patients. Twenty patients received only supportive care. The median follow-up duration was 34 months and the median overall survival from diagnosis of LC was 14 weeks (95% confidence interval [CI] 12, 16). In univariate analysis, encephalopathy, Eastern Cooperative Oncology Group (ECOG) performance status, low initial cerebrospinal fluid (CSF) glucose, high initial CSF protein, high initial CSF white blood cell count, treatment with ITC, systemic therapy with epidermal growth factor receptor tyrosine kinase inhibitors or cytotoxic chemotherapy, whole-brain radiotherapy (WBRT), ventriculoperitoneal (VP) shunt operations, and negative cytologic conversion after ITC were identified as variables that had prognostic influence on survival. In multivariate analysis, poor ECOG performance status (p = 0.026), high protein level of CSF (p = 0.027), and high initial CSF WBC count (p = 0.015) remained significant predictors of poor prognosis for survival, whereas ITC (p < 0.001), EGFR-TKI use (p = 0.018), WBRT (p = 0.009), and VP shunt operation (p = 0.013) remained significant predictors of favorable prognosis for survival. Conclusions: Even though the prognosis of LC from NSCLC is poor, small subsets of these patients survive longer. Our results suggest that more active treatment strategies including ITC, WBRT, and EGFR-TKI use might improve clinical outcomes in NSCLC patients with LC and good performance status, low initial CSF protein and WBC counts.
L eptomeningeal carcinomatosis (LC) is a rare but rapidly fatal clinical condition occurring in 1% to 5% of all patients with solid tumors. [1] [2] [3] [4] [5] [6] [7] Without therapy, the median survival time is only 4 to 6 weeks, but survival can be extended to 4 to 6 months with treatment in selected patients. 7 Adenocarcinoma is the histological indicator most frequently associated with LC, and breast cancer, lung cancer, and melanoma are the most common primary tumors resulting in LC with rates up to 20%. 2, 8 Recently, the incidence of LC has increased because of new, effective anticancer treatments against primary tumors and improvements in neuroimaging techniques. 4, 9 Prolonged survival has been particularly evident in certain lung cancer patients with the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as gefitinib or erlotinib.
The treatment of LC usually includes intrathecal chemotherapy (ITC), systemic therapy, radiotherapy, and surgery. Surgery and radiotherapy are mainly reserved for the palliation of hydrocephalus or symptoms resulting from focal lesions. [2] [3] [4] 9, 10 Systemic chemotherapy remains an option to treat systemic disease, but data on lone systemic chemotherapy in patients with LC are lacking. Although there are recent reports on EGFR-TKI use in patients with LC, these studies included only a small number of patients. [11] [12] [13] As for ITC, there is no consensus regarding its survival benefit 14, 15 because of heterogeneous results from several randomized studies on intrathecally applied cytotoxic agents.
Today, the debate about the optimal treatment for LC continues, and no standard guidelines exist. Given that previous studies of LC included various types of malignancies such as breast cancer, lung cancer, melanoma, and other hematologic malignancies, the heterogeneity of disease makes it difficult to identify prognostic factors associated with LC. Accordingly, we were prompted to investigate LC solely in patients with non-small-cell lung cancer (NSCLC). The purpose of this study was to identify prognostic factors associated with LC in NSCLC patients according to clinical features, laboratory findings, and treatment modalities, which in turn may contribute to evidence-based clinical practice for physicians.
PATIENTS AND METHODS

Patients
We retrospectively reviewed 149 NSCLC patients who were diagnosed with LC at the Samsung Medical Center in Seoul, Korea, between 2001 and 2009. Only patients with LC confirmed by cytology were included in this study. According to clinical guidelines, CSF exploration was only performed in patients who developed neurological problems or had abnormal brain imaging.
Parameters
We evaluated demographic data, clinical features, tumor-related features, CSF findings, and treatments. The clinical features at LC presentation were classified into five groups: 19 (1) supratentorial symptoms (seizures, cognitive impairment, dysphasia, difficulty in walking, sensory impairment, unexplained weakness, decreased visual acuity), (2) infratentorial symptoms (cranial, radicular, or spinal nerve involvement), (3) endocranial hypertension, (4) endocranial hypertension plus other symptoms, and (5) encephalopathy.
In terms of tumor-related features, the histology, the presence or absence of an EGFR gene mutation, and the presence or absence of concurrent brain metastases at the time of LC diagnosis were analyzed. CSF findings that were assessed included fluid cytology, opening pressure, glucose concentration, and protein concentration at LC presentation. With respect to treatment, we evaluated whether intrathecal chemotherapy, systemic chemotherapy, EGFR-TKIs, or radiotherapy were used.
Treatment of LC
Management decisions in the treatment of LC were made at the treating physician's discretion. For intrathecal chemotherapy, methotrexate at a dose of 15 mg twice a week was delivered via Ommaya reservoir until the cytology cleared. Cytological analysis of CSF was performed just before each administration of intrathecal chemotherapy. After cytology was deemed clear, patients received intrathecal methotrexate once a week for 4 weeks and subsequently once every 2 weeks for the next 3 months. Systemic therapy included cytotoxic chemotherapy and EGFR-TKIs such as gefitinib or erlotinib. Whole-brain radiotherapy was usually performed at a dose of 30 Gy in five to 10 daily fractions.
Statistical analysis
Overall survival was defined as the period from LC diagnosis until death or last follow-up. The date of LC diagnosis was defined as the date of the first positive cytologic study. Kaplan-Meier estimates were used in the analysis of the timeto-event variables and 95% confidence intervals (CI) were calculated for the median time to event. Survival comparisons by univariate analysis were estimated using the log-rank test. Cox's proportional hazard model was used for multivariate analyses. A p value of less than 0.05 was considered to be statistically significant.
RESULTS
Characteristics of Patients
Demographic and clinical characteristics of the patients are summarized in Table 1 . The median age at the time of the LC diagnosis was 58 years (range, 34-80). All patients were of Korean descent and the ratio of men to women was 1.04. A large majority of the patients were found to have adenocarcinoma histology (95.1%) and most were initially diagnosed with stage IV disease (79.9%). Testing for an EGFR gene mutation was only performed in 23 patients; 13 of those patients (59.1%) were determined to have an activating EGFR gene mutation. The EGFR mutations included a deletion mutation in exon 19 that was found in seven patients, an L858R point mutation in exon 21 that was found in five patients, and point mutations in exons 18 and 20 that were found in only one patient. One of the patients with an L858R point mutation was also found to have a point mutation in exon 20. Among 149 LC patients, 
(22.8)
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor. except 26 patients who had initial LC at the diagnosis of lung cancer, initial brain magnetic resonance imaging (MRI) was performed for 84 patients, and 36 patients without initial brain MRI developed LC subsequently. Sixty-two patients (41.6%) had a history of previous brain metastasis and were treated with gamma-knife surgery or whole-brain irradiation.
Patterns and Clinical Presentation of LC
The median interval from diagnosis of lung cancer to the diagnosis of LC was 11.1 months (range, 0-112) ( Table 2) . Twenty-six patients (17.4%) presented with LC at the initial diagnosis of NSCLC, and 64 patients (43.0%) had a responsive or stable status of the primary tumor at the time of LC diagnosis. The most frequent presenting symptoms of LC were symptoms of endocranial hypertension (category 3) such as headache, nausea, or vomiting. Most patients (n = 129, 86.6%) had good ECOG performance status (ECOG PS 0-2).
An elevated opening pressure on lumbar puncture was noted in 41.6% of the patients. Among the patients, 21.5%, 67.1%, and 47.7% had low CSF glucose (normal range, 45-60 mg/dL), high CSF protein (normal range, 20-40mg/dL), and high CSF WBC count (normal range, 0-7/µl), respectively. Gadolinium-enhanced MRI demonstrated leptomeningeal enhancement in 94% of the patients, hydrocephalus in 17.4% of the patients, and concurrent brain parenchymal metastasis in 65.8% of the patients. Figure 1 illustrates the increased incidence of LC in NSCLC over time.
Treatments
Treatment methods after LC diagnosis are summarized in Table 3 . ITC was administered to 109 patients (73.2%), and the median number of ITC administrations was 9 (range, 1-27); only 15 patients achieved cytologically negative conversion. In addition to IT chemotherapy, 47 patients (31.5%) were treated with whole-brain irradiation, and 36 patients (24.1%) were treated with systemic therapy. Twenty patients (13.4%) underwent radiotherapy or systemic therapy without ITC, and 20 patients (13.4%) only received supportive care.
Among those patients who were treated with systemic therapy, EGFR TKIs were used in 24 patients and cytotoxic chemotherapy was used in 25 patients. Among the 25 patients who were treated with cytotoxic chemotherapy after LC diagnosis, seven patients had platinum-based chemotherapy and 18 patients had monotherapy with pemetrexed (n = 10), docetaxel (n = 5), or gemcitabine (n = 3). VP shunt operations were performed in 23 patients (15.4%) for palliation of hydrocephalus.
Survival and Prognostic Factors
The median overall survival was 14 weeks (95% CI [12] [13] [14] [15] [16] ) (Fig. 2) . Certain clinical characteristics, CSF findings, and treatment modalities that were useful in predicting survival after diagnosis of LC were included in a univariate analysis using a log-rank test. Encephalopathy (p = 0.008), poor performance status (ECOG PS>2) (p < 0.001), high CSF protein level (p = 0.002), low CSF glucose level (p = 0.002), and high CSF WBC count (p < 0.001) predicted poor survival. In contrast, application of intrathecal chemotherapy (p < 0.001), EGFR-TKIs (p < 0.001), cytotoxic chemotherapy (p < 0.001), whole-brain irradiation (p < 0.001), VP shunt operation (p = 0.015), and negative cytologic conversion (p = 0.049) predicted favorable survival. The median overall survival in patients with an ECOG PS of 2 or less was longer than that of patients with an ECOG PS score of 3 or 4 (15 weeks versus 6 weeks, p < 0.001; Fig. 3A) . Patients who received IT chemotherapy demonstrated longer overall survivals compared with those who did not receive IT chemotherapy (17 weeks versus 8 weeks, p < 0.001; Fig. 3B ). Twenty-four patients received EGFR-TKIs after a diagnosis of LC, and these patients had longer survival periods compared with patients who did not receive EGFR-TKIs (38 weeks versus 13 weeks, p < 0.001; Fig. 3C ). Systemic cytotoxic chemotherapy and WBRT were also correlated with prolonged survival in patients with LC ( Fig. 3D and 3E) .
We summarized the baseline characteristics and treatment responses of patients who received EGFR-TKIs after the diagnosis of LC (Supplemental Digital Content 1, http:// links.lww.com/JTO/A354). Among 24 patients, four had an EGFR mutation, and all those patients had partial extra-brain responses after EGFR-TKI use. Another 20 patients took EGFR-TKIs without undergoing the test for EGFR mutations. Among those patients, 11 were nonsmoking women, which is a population with a high probability of having EGFR mutations. Nine patients, however, were smokers or men who had low probabilities of EGFR mutations. Smoking tended to be associated with extra-brain responses after EGFR-TKI use. More specifically, among nine smokers, seven patients without EGFR mutation showed unresponsive or progressive disease after EGFR-TKI treatment, whereas the majority of the 15 never-smokers showed at least a partial response to EGFR-TKI.
We performed a multivariate analysis, which included factors that were statistically significant in the univariate analysis for survival. Prognostic factors for poor overall survival, which retained statistical significance at the multivariate level (Table 4) .
DISCUSSION
To the best of our knowledge, to date, this is the largest study conducted on LC of NSCLC. A notable strength of this study was the exclusion of small-cell lung cancer patients to only evaluate cases of NSCLC with cytology-positive CSF, thereby minimizing the inherent bias resulting from including heterogenic tumor types.
The interval between the diagnoses of lung cancer and LC varied to a great extent with a range of 0 to 112 months (median 11.1 months). Sudo et al. 19 reported retrospective data on 37 lung cancer patients with LC in 2006. In that study, the time from the date of diagnosis of lung cancer to the date of diagnosis of LC similarly ranged from 2 days to 8 years (median 407 days). Of note in our study, 26 patients (17.4%) presented with LC at the time of initial lung cancer diagnosis and another 64 patients (43.0%) had a partial response or stable disease of the primary tumor at the time of LC diagnosis. These findings suggest that physicians should be attentive to newly diagnosed cancer patients and patients with stable disease, rather than solely focusing on patients with progressive disease or terminal status. The most frequent symptoms related to LC were related to endocranial hypertension, such as headache, nausea, and vomiting, which is consistent with previous reports. [20] [21] [22] Although most patients had neurological symptoms, five patients did not present with clinical symptoms at the time of diagnosis of LC, but rather LC was suspected based on brain imaging. Most patients (n = 140) demonstrated leptomeningeal enhancement on the initial brain MRI whereas a small number of patients (n = 9) had no leptomeningeal enhancement at the time of LC diagnosis. The findings suggest that when patients have typical symptoms of LC without definitive findings with brain imaging, further evaluation with a CSF exam is warranted.
Although LC is considered to be a fatal disease 2, 3, 7 with a median overall survival of only 1 to 4 months with or without treatment, a subset of LC patients with breast cancer or lymphoid malignancies has been shown to achieve disease-free survival of a year or more. 3, 7, 23 In our study, the median survival was only 14 weeks, and the overall survival ranged from 1 week to 29 months. Chamberlain and Kormanik 22 reported that the median survival was 5 months in a prospective study of 32 NSCLC patients with LC and good performance status. All 32 patients in that study received ITC, and 16 patients also received radiotherapy. The longer survival demonstrated in that study might be attributable to the exclusion of patients with poor performance status. In contrast, Chuang et al. 21 reported retrospective data of 34 lung cancer patients with LC diagnoses from 1992 to 2002 whose median survival was only 5.1 weeks. A Japanese study calculated an average survival of 106 days (range, 10-392) which was similar to our results.
The use of EGFR-TKIs in that Japanese study as well as our own may in part have contributed to the prolonged survival in a specific group of patients. 19 In our study, testing for EGFR mutations was performed in only 23 patients and among them, 13 patients had EGFR mutations. Although we presumed that patients with EGFR mutations who were treated with EGFR-TKIs after LC diagnosis would have longer survival periods, a significance difference was not evident, possibly because of the small sample of patients. Patients who were clinically suspected but never confirmed to have EGFR mutations also took EGFR-TKIs after LC diagnosis, and they showed longer survival times than patients who did not take EGFR-TKIs.
In our study, the incidence of LC after NSCLC increased over time (Fig. 1) . With the introduction of many different salvage therapy regimens including docetaxel, pemetrexed, or EGFR-TKIs in the treatment of NSCLC, patients are increasingly more likely to be treated aggressively using more than two lines of therapy, resulting in a prolonged survival. The median survival of patients with activating EGFR mutations was double that of patients with wild-type EGFRs, and these patients might be more prone to brain or LC metastasis as survival time increases.
In our analysis, the univariate analysis identified encephalopathy, ECOG PS, CSF findings (protein, glucose level, and WBC count), application of ITC, EGFR-TKI use, cytotoxic chemotherapy, WBRT, VP shunt operation, and cytologic response of CSF as prognostic factors with significant impact on survival. In multivariate Cox regression analysis, poor ECOG PS, high CSF protein level, and high CSF WBC count were therapy-independent predictors of poor survival. Moreover, the application of ITC, EGFR-TKI use, WBRT, and VP shunt operation were positive prognostic factors for survival.
Previous studies indicated that cancer type, age (old or young), poor PS, time between primary tumor and LC diagnosis of 12 months or lesser, serum albumin level, CSF glucose level, CSF lactate level, compartmentalization of CSF, coexistent bulky metastatic disease in the CNS, and the presence of encephalopathy were negative prognostic factors and that the application of systemic chemotherapy was a positive prognostic factor for survival. 2, 4, 20, 24 The influence of these prognostic factors, however, was not confirmed in multivariate analyses, and these reports were limited by including varied types of cancer patients with LC. Although several reports that focused on only lung cancer patients with LC are available, 19, 21, 25 small sample sizes limit the ability to draw conclusions about the prognostic factors. Nakamura et al. reported data on 69 lung cancer patients with LC. 26 They concluded that good PS at the time of LC diagnosis was a favorable prognostic factor. In addition, EGFR-TKI use and RT for brain and/or spinal cord were considered possible treatment options for these patients. These findings are similar to our results. Recently, a report of 50 NSCLC patients with LC concluded that systemic therapy, particularly using EGFR-TKIs in addition to ITC, might confer a survival benefit. In our data, certain CSF findings, the application of ITC, and VP shunt operations had significant impact on survival. However, because of the retrospective nature of the current study, a cautious interpretation of the findings and future prospective confirmatory studies are warranted. Nevertheless, our study is the largest to date and had sufficient statistical power to conduct multiple analyses.
Although ITC is a preferred treatment for LC patients, there is no universally accepted data supporting its effectiveness. Bokstein et al. 27 compared patients who were treated with systemic chemotherapy and radiotherapy with ITC versus without ITC and found that there was no significant difference in overall survival. On the one hand, Boogerd et al. 28 performed a randomized trial in breast cancer patients with LC and similarly did not find a survival benefit in using intra-CSF chemotherapy. On the other hand, Bruna et al. 20 reported that intrathecal treatment was independently associated with a longer survival in a similar subset of patients.
Given the heterogeneous modalities of treatment that were used in this retrospective study, the precise roles of those various treatments remain controversial and need to be validated in a prospective study. However, in contrast to many previous reports 4, 24 that suggested that systemic chemotherapy prolonged survival in LC, our results indicated that only ITC, EGFR-TKIs, WBRT, and VP shunt operations were associated with prolonged survival. Such discrepancies may be attributable to the heterogeneous types of cancer included in different studies.
In conclusion, our large sample size of patients with NSCLC and LC demonstrated that good ECOG PS, low initial CSF protein level, and low initial CSF WBC count were favorable prognostic factors. Active treatments with ITC, EGFR-TKIs, WBRT, and VP shunt operations additionally prolonged survival. Because our data only included patients of Korean descent and the population in this series was relatively young, predominantly nonsmoker, female, and exclusively had adenocarcinoma histology, our results cannot be directly applied to Western patients with different demographics and characteristics from ours. Considering the fatal clinical courses of NSCLC patients with LC, more active treatment strategies including ITC, EGFR-TKI use, WBRT, and VP shunt operation may be associated with improvement of clinical outcomes in the subset of NSCLC patients with LC.
